{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0","upperLimit":"114","value":"57"},{"groupId":"OG001","lowerLimit":"2","upperLimit":"115","value":"56.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"20"}],"units":"Participants"}],"description":"Median OS for thalidomide/Dexamethasone participants vs. VAD participants. Months from On Study to Expired/Last Date Known Alive.\n\nInvestigators had planned to accrue 176 participants to calculate median overall survival.","dispersionType":"Full Range","groups":[{"description":"VAD (vincristine, adriamycin, dexamethasone). Vincristine and adriamycin was administered by continuous infusion via a venous catheter for 96 hours every 28 days. Each 28 days is considered one \"cycle\" of therapy. Patients were to receive 4 to 6 cycles of therapy. Dexamethasone was taken in pill form. During the first 2 cycles it was taken on days 1-4, 9-12, 17-20. For all other cycles dexamethasone was taken only on days 1-4. Patients were randomized to receive zoledronic acid IV on either Day 1 or 15 of each cycle.","id":"OG000","title":"Active Comparator: VAD Treatment"},{"description":"Thalidomide was taken orally once every day in the evening for four to six months. The dexamethasone was taken in a pill form. During the first 2 cycles it was taken on days 1-4, 9-12, 17-20. For all other cycles dexamethasone was taken only on days 1-4.","id":"OG001","title":"Active Comparator: Thalidomide and Dexamethasone Treatment"}],"paramType":"MEDIAN","populationDescription":"All participants with evaluable follow-up data.","reportingStatus":"POSTED","timeFrame":"Up to 10 Years","title":"Overall Survival (OS), by Treatment Arm","type":"SECONDARY","unitOfMeasure":"months"}